Innovation, Development & Entrepreneurship Advisory (IDEA) Board
The IDEA Board champions innovation and entrepreneurship across the Johns Hopkins University, providing the vision and strategy by which Johns Hopkins will bring the next generation of discoveries to market. This group of stakeholders from industry, academia, startups, and the broader ecosystem is also helping to catalyze new economic activity and partnerships that will build a better Baltimore.
Johns Hopkins Technology Ventures
Christy Wyskiel is Senior Advisor to the President of Johns Hopkins University for Innovation & Entrepreneurship and Executive Director of Johns Hopkins Technology Ventures. Her portfolio includes technology transfer, the FastForward innovation hubs, and commercial research partnerships for the University. Christy is a seasoned entrepreneur, investor, and ecosystem builder with 20+ years of experience primarily focused on the life sciences and healthcare industries.
Conscious Venture Lab, CEO and Founder
SHIFT Ventures, Managing Director
As CEO and founder of Conscious Venture Lab & Managing Partner of SHIFT Ventures, Jeff Cherry is an evangelist for the transformation of capitalism. In 2006, he became co-head of research for Multi stakeholder investment strategies for a multi-billion dollar hedge fund based in Stamford, CT and spent 20 years as founder and CEO of Lloyd Lamont Design, Inc. a multifaceted management, architecture and technology consulting firm. As a thought leader in the areas of stakeholder management and the emerging discipline of Conscious Capitalism®, Jeff formed Concinnity Advisors, a hedge fund focused on identifying and investing in companies operating from a more holistic, long-term value mindset. He received his Bachelors of Architecture and Masters of Science in Architecture from The Catholic University of America in Washington, D.C., and completed extended executive study
courses at the Stanford Graduate School of Business.
Charles (Chuck) Clarvit (Arts & Sciences ’78)
Clarvit Capital Family Office, CEO
Chuck Clarvit is CEO of his family office Clarvit Capital. Prior to that, he was CEO of Vinci Partners US and a former Managing Director and Co-Head of BlackRock Alternative Advisors, the firm’s fund of funds platform. He joined BlackRock in 2007 following acquisition of the fund of funds business of Quellos Group, LLC. He is a Hopkins graduate and a member of the Johns Hopkins University Board of Trustees. Chuck is an early philanthropic supporter, investor and venture connector for Johns Hopkins.
Nick Culbertson (Arts & Sciences ’12, Medicine)
Protenus, CEO, CO-Founder
Nick Culbertson is the Co-Founder and CEO of Protenus, a leading healthcare compliance analytics platform. Nick is an eight-year U.S. Army veteran and completed his service as a highly decorated U.S. Special Forces operator (Green Beret). He was awarded two Bronze Star medals during his service, where he specialized in human intelligence network gathering and analysis. He is a Hopkins graduate and spent four years as a biomedical researcher there at the School of Medicine. He also helps run The 6th Branch, a veteran-led community service organization in East Baltimore.
The Abell Foundation, CEO
As President, Robert C. Embry, Jr. leads The Abell Foundation’s efforts to improve the quality of life for people in Maryland and Baltimore City. Prior to joining the Foundation in 1987, Bob served as President of the Board of School Commissioners for Baltimore City, Assistant Secretary of the U.S. Department of Housing and Urban Development, and Commissioner of the Department of Housing and Community Development for Baltimore City. The Abell Foundation was an early funder of the build out of our inaugural innovation space in the Rangos Building.
Lion Brothers, CEO
Owings Mills, MD
Suzy is Chairman and CEO of Lion Brothers, and is a passionate Entrepreneur, Board Director, Corporate Advisor and Public Sector leader. She brings an expertise in strategy, digital manufacturing, innovation and entrepreneurship. Over her twenty five + years at Lion, has transitioned Lion from one of America’s first embroidery companies into a leading material science and innovation company within the global apparel industry. Suzy has been an advisor to several of our manufacturing focused spin out companies.
Professor of Ophthalmology and Director of the Johns Hopkins Center for Nanomedicine
Justin Hanes is the Lewis J. Ort Endowed Professor of Ophthalmology and Director of the Center for Nanomedicine at the Johns Hopkins University, where he also holds faculty appointments in the departments of Biomedical Engineering, Chemical & Biomolecular Engineering, Environmental Health Sciences, Neurosurgery, Oncology, and Pharmacology & Molecular Sciences. He is an inventor on more than 125 patents and patent applications focused in the area of advanced delivery systems that make drugs safer and more effective. Companies launched based on these patents include Advanced Inhalation Research (acquired by Alkermes), Civitas Therapeutics (acquired by Acorda Therapeutics), Kala Pharmaceuticals (IPO), and GrayBug Vision. Justin has been an advisor and mentor to numerous Johns Hopkins faculty members and startups.
Brown Advisory, CEO
Mike Hankin is President and Chief Executive Officer of Brown Advisory Holdings Incorporated, a position he has held since the firm became independent from Bankers Trust/Alex. Brown & Sons on June 30, 1998. He has spent over 25 years assisting a wide range of individuals and institutions on their investment and financial matters. He was formerly a partner with the law firm of Piper & Marbury (now ―DLA Piper). He is Vice Chairman of the Johns Hopkins Medicine Board, a Trustee of the University, and a member of the Applied Physics Lab Board of Managers. He was an early philanthropic supporter of a commercial analyst role at Johns Hopkins Technology Ventures and is supporting our student entrepreneurship efforts.
Isaac Kinde, MD, Ph.D. (Medicine ‘15)
Thrive Earlier Detection, Co-Founder, Head of Research & Innovation
Isaac’s expertise in molecular diagnostics stems from his graduate school training in the lab of Thrive’s founders at Johns Hopkins University. His thesis research produced novel diagnostics based on improvements to massively parallel DNA sequencing. The technologies he co-invented with Thrive founders have subsequently enabled the earlier detection of several different cancers and other genetic diseases from a wide variety of clinical specimens. In 2012, Isaac was honored among Forbes’ 30 Under 30 in science and healthcare. Isaac holds a B.S. in biological sciences from the University of Maryland, Baltimore County, where he was a Meyerhoff Scholar, a Ph.D. in cellular and molecular medicine, and an M.D. from the Johns Hopkins University School of Medicine.
Ethan Leder (Arts & Sciences ‘84)
Precision Medicine Group, Co-Founder and Executive Chairman
Ethan D. Leder is the Co-Founder and Executive Chairman of Precision Medicine Group. Over the past 25 years, he has been an entrepreneur focused on building and managing innovative, market-leading companies that address critical gaps in the healthcare industry. Prior to Precision Medicine Group, Leder was the Founder and CEO of United BioSource Corporation (UBC), which became the leader in real-world research addressing safety, value, and comparative effectiveness for the life science industry. Before UBC, Ethan was the Founder and CEO of U.S. Bioservices, Inc., which addressed a growing need for personalized, direct-to-patient distribution of high-cost biotechnology for serious medical conditions. Ethan is a Johns Hopkins Trustee and the lead funder of our student entrepreneurship programs on the Homewood campus.
Former Deputy Secretary of Treasury and Director at T. Rowe Price
Currently, Mary is a Senior Fellow for 21st Century Cities Initiative at Johns Hopkins University and a private investor. She previously served as the U.S. Department of the Treasury’s Under Secretary for Domestic Finance and as Assistant Secretary of the Treasury for Financial Markets. Prior to joining Treasury, Miller spent 26 years working for T. Rowe Price Group, Inc., where she was the director of the Fixed Income Division and a member of the firm’s Management Committee. Mary was the lead author of the 21st Century Cities Initiative Report, “Financing Baltimore’s Growth: Measuring Small Companies’ Access to Capital” and is a regular advisor to Christy Wyskiel on innovative financing mechanisms.
Heather Murren (Arts & Sciences ’88)
Las Vegas, NV
Ms. Murren served as a Federal Commissioner on the Financial Crisis Inquiry Commission from 2009-2011. The Report of the Financial Crisis Inquiry Commission was published in 2011 and was critically acclaimed and a New York Times bestseller. Ms. Murren was a cofounder and had previously served as the first chairman of the board for Nevada Cancer Institute, a non-profit cancer research and treatment center. In 2002 she retired as a managing director, Global Securities Research and Economics, of Merrill Lynch, where she was group head for the Global Consumer Products Equity Research effort. She is a Johns Hopkins University Trustee. She has advised several Johns Hopkins startups and was an early proponent of the Innovation & Entrepreneurship Advisory Board.
Myra Norton has been the COO of Arena since 2012 after a rich career in data and analytics. Norton has extensive academic experience as an administrator and professor in mathematics and statistics at Temple University, Towson University, and the United States Naval Academy. Norton graduated from the University of Alabama as a Faculty Scholar, earning a BS in Math Education. She was then awarded a Future Faculty Fellowship and earned an MA in Mathematics and an MS in Statistics at Temple University. Following her work as a faculty member and administrator in the College of Science and Technology, Norton worked as a labor analyst at Northrop Grumman. She left Northrop Grumman to help launch Community Analytics, a start-up focused on applying social network analysis to drive sales and marketing effectiveness. Norton was named CEO of Community Analytics in 2007, and led all aspects of the organization until her move to Arena in 2012. In the community, Norton serves as a member and past chair of the Industrial Advisory Board for the College of Engineering and Information Technology at UMBC; the current Chair of the Board of Directors for TEDCO; the Chair of a Maryland task force to increase the support of women entrepreneurs in the state; and the Chair of the BmoreSTEM infrastructure workgroup, working with public and private entities to increase access and retention of students in STEM fields. She mentors college students and young professionals in the Baltimore area, and she works with high school students through the National Foundation for Teaching Entrepreneurship (NFTE).
Morris Offit (Arts & Sciences ’57)
Offit Capital Advisors LLC, Chairman
Morris Offit is the Chairman of Offit Capital Advisors LLC, a wealth management advisory firm in New York. From 2002 to June 2007, he was the Co-Chief Executive Officer of Offit Hall Capital Management LLC, also a wealth management advisory firm with offices in New York and San Francisco. Prior to that time he was founder and CEO of OFFITBANK, a wealth management private bank, which merged into Wachovia Bank in 1999. He is Trustee Emeritus and Past Chairman of the Board of Trustees of Johns Hopkins University and Medicine. Morris was an early proponent of the creation of the Innovation & Entrepreneurship Advisory Board and has been a long-time support of innovation across the university.
Chandra Ramanathan, Ph.D., M.B.A.
Global Head, Pharma R&D Open Innovation, Bayer
Chandra Ramanathan leads the Open Innovation Centers (OICs) around the world (US, Europe, Japan, China and Singapore) for Bayer. The OICs focus on early access to breakthrough technologies, management of strategic alliances, and public private partnerships. Chandra’s previous roles at Bayer include Global Program Lead for External Innovation/Life Sciences, Global Launch Team Leader (copanlisib) and Head of Global Oncology Pipeline Marketing. Prior to joining Bayer, Chandra worked at Wyeth (Pfizer) and Bristol-Myers Squibb in various roles in Drug Discovery, Applied Genomics, and Business Development & Licensing. Chandra earned an MBA from the Columbia Business School, a PhD in Genomics/ Bioinformatics, an MS in Medicinal Chemistry, and a BS in Pharmacy. Chandra is an adjunct assistant professor at the Tufts School of Medicine and is on the Board of Directors of MassBIO, the Massachusetts Biotech Council.